التداخل بين لاموتريجين وليفونورجيستريل وإيثينيل إستراديول

Decrease in levonorgestrel component by 19%.

Concomitant Use with Estrogen-Containing Products, Including Oral Contraceptives Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology ( 12.3 )] .

Dosage adjustments will be necessary in most patients who start or stop estrogen-containing oral contraceptives while taking SUBVENITE [see Dosage and Administration ( 2.1 )] .

Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%.

Specific dosing guidance for these drugs is provided in the Dosage and Administration section, and, for women taking estrogen-containing products, including oral contraceptives, in the Warnings and Precautions section [see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.9 )] .

Table 4 Significant Drug Interaction Information for Drugs Co-Administered with CHCs Lamotrigine Clinical effect Concomitant use of CHCs with lamotrigine may significantly decrease systemic exposure of lamotrigine due to induction of lamotrigine glucuronidation [see Clinical Pharmacology (12.3) ].

Decreased systemic exposure of lamotrigine may reduce seizure control.

Consult the approved product labeling for lamotrigine.